{"analyses":[{"groupDescription":"Acute toxicity","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.21","pValueComment":"Two-side significance level = 0.05","statisticalMethod":"Fisher Exact"},{"groupDescription":"Late toxicity","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.18","pValueComment":"Two-sided significance level = 0.05","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.8","upperLimit":"87.5","value":"83.7"},{"groupId":"OG001","lowerLimit":"75.9","upperLimit":"84.1","value":"80.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"title":"Acute"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.8","upperLimit":"25.3","value":"21.1"},{"groupId":"OG001","lowerLimit":"21.0","upperLimit":"30.3","value":"25.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"351"},{"groupId":"OG001","value":"343"}],"units":"Participants"}],"title":"Late"}],"denoms":[{"counts":[{"groupId":"OG000","value":"361"},{"groupId":"OG001","value":"360"}],"units":"Participants"}],"description":"Acute radiation therapy toxicities (within 90 days from start of radiation therapy) and systemic effects at any time were scored using Common Toxicity Criteria (CTC) version 2.0. Late RT toxicities (\\> 90 days from start of radiation therapy) were scored by the Radiation Therapy Oncology Group (RTOG)/European Organisation for. Research and Treatment of Cancer (EORTC) criteria. Both criteria grades toxicity severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event/toxicity data.","dispersionType":"95% Confidence Interval","groups":[{"description":"Standard fractionation radiation therapy with concurrent cisplatin followed by conventional surgery for select patients.","id":"OG000","title":"Standard Fractionation RT + Cisplatin"},{"description":"Accelerated fractionation radiation therapy by concomitant boost with concurrent cisplatin followed by conventional surgery for select patients.","id":"OG001","title":"Accelerated Fractionation RT + Cisplatin"}],"paramType":"NUMBER","populationDescription":"Eligible patients who did not withdraw consent","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Follow-up schedule from end of treatment: 6-8 weeks, every 3 mo. for 2 yr., then every 6 mo. for 3 yr., then yearly. Maximum follow-up at time of analysis was 6.5 years.","title":"Percentage of Participants With Toxicity Grade 3 or Higher","type":"SECONDARY","unitOfMeasure":"percentage of participants"}